Intravitreal Ranibizumab versus Razumab in treatment naïve diabetic macular edema
Background: Diabetic macular edema (DME) is a leading cause of vision impairment globally among working population, with anti-vascular endothelial growth factor (anti-VEGF) therapies being the standard treatment. The high cost of anti-VEGF drive use of biosimilars like Razumab®. This study provides...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
KIMS Foundation and Research Center
2025-06-01
|
| Series: | Journal of Medical and Scientific Research |
| Subjects: | |
| Online Access: | https://jmsronline.com/archive-article/Ranibizumab-Razumab-diabetic-macular-edema |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|